# RTW Investments

> RTW Investments is a VC fund backing Biotechnology and Health Care. See 146 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 146
- Last investment: Aug 2026
- Lead investor: 29%
- Fund size: $458M
- Last fund: Jul 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/rtw-investments-llc
- X (Twitter): https://twitter.com/rtwlp
- Website: http://www.rtwfunds.com/

RTW Investments is a VC fund in New York focused on Biotechnology and Health Care. RTW Investments makes investments in forward-thinking healthcare companies. It invests across the entire company lifecycle, including company creation, early-stage venture capital, alternative financing, and public company investments. The company is headquartered in New York with offices in London and Shanghai.

## Contacts

5 contacts available for RTW Investments. Shizune tracks 9 team members at RTW Investments. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/rtw-investments-llc?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 79 | 54% |
| Health Care | 45 | 31% |
| Therapeutics | 35 | 24% |
| Pharmaceutical | 26 | 18% |
| Medical | 25 | 17% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 32 | 22% |
| Series B | 30 | 21% |
| Series C | 17 | 12% |
| Series A | 12 | 8% |
| Series D | 10 | 7% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 72 | 49% |
| Switzerland | 4 | 3% |
| China | 3 | 2% |
| United Kingdom | 3 | 2% |
| Canada | 2 | 1% |

9 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Lauren Lee | Research Analyst | 1 | https://shizune.co/investors/profile/lauren-lee-b1a9 |
| Naveen Yalamanchi | Partner | 5 | https://shizune.co/investors/profile/naveen-yalamanchi |
| Robert Aurigema | Chief Financial Officer | 0 | https://shizune.co/investors/profile/robert-aurigema-8693 |
| Sabera Loughran | Chief Operating Officer | 0 | https://shizune.co/investors/profile/sabera-loughran-919f |
| Gaurav Shah | Entrepreneur in Residence | 0 | https://shizune.co/investors/profile/gaurav-shah-2 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tarsus Pharmaceuticals | Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases acrosstherapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis. | $125M | Post-IPO Equity | Aug 06, 2026 |  |
| Obsidian Therapeutics | Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with newfunctions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies. | $350M | Post-IPO Equity | Aug 04, 2026 |  |
| Mentari Therapeutics | Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine. | $200M | Private Equity | Jul 22, 2026 |  |
| Pyxis Oncology | Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novelantibody-based immunotherapies.It was founded in 2019 and is based in Boston, Massachusetts. | $50M | Post-IPO Equity | Jun 30, 2026 |  |
| Lycia Therapeutics | Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M | Series D | Jun 25, 2026 |  |
| Artiva Biotherapeutics | Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technologicalbarriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates. | $300M | Post-IPO Equity | May 08, 2026 |  |
| Windward Bio | Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M | Series B | May 04, 2026 |  |
| Amani Therapeutics | Amani Therapeutics is breaking down barriers with breakthrough technology to provide effective medicines for those suffering from significant psychiatric illnesses, restoring hope and stability and allowing them to live more fulfilling lives. | $25M | Series A | Mar 23, 2026 |  |
| Prolium | Prolium is a biotechnology company, which specializes in providing breakthrough therapies to the patients with autoimmune diseases. | $50M | Series A | Mar 03, 2026 |  |
| Candel Therapeutics | Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostatecancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster. | $100M | Post-IPO Debt | Feb 19, 2026 |  |

10 of 146 investments shown.

## Co-investors
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 32 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 31 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 25 deals together
- [Venrock Healthcare Capital Partners](https://shizune.co/investors/profile/venrock-healthcare-partners) — VC Fund, 23 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 20 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 20 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Life Science Investors in Switzerland](https://shizune.co/investors/life-science-investors-switzerland)

## FAQ

### What does RTW Investments invest in?

RTW Investments invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 146 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact RTW Investments?

Public channels for RTW Investments include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at RTW Investments?

The team at RTW Investments includes Lauren Lee (Research Analyst), Naveen Yalamanchi (Partner) and Robert Aurigema (Chief Financial Officer), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co